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Caveat emptor: direct-to-consumer supply and 
advertising of genetic testing 
Roxanne Mykitiuk, BA, LLB, LLM 
Most Canadians who wish to access genetic diagnos-
tic and susceptibility tests do so through the publicly 
funded health care system. 1 However, some genetic 
tests are not covered under that system, and indi-
viduals may seek to purchase them from private 
sources. The Internet has become both a vehicle for 
advertising and a means to convey Canadians to pri-
vate genetic testing sources. Usually, peo-
ple are directed to international provid-
ers,2 but in the case of tests for a number 
of conditions such as breast and ovarian 
cancer they are also directed to local pri-
vate laboratories such as the multi-city 
branches of MDS Laboratory Services, 
whose home office is in Toronto. 
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recent advances in genetics: universities and govern-
ment research centres frequently seek collaboration 
with (and funding from) private genome research 
companies, which in turn increasingly are developing 
cooperative relationships with pharmaceutical com-
panies.3 In the context of DTC adve1tising and supply 
of genetic testing services, this raises concerns about 
Normally, people interested in acces-
sing genetic testing services must do so 
through a physician who may order the 
test. However, a few companies market 
their genetic testing products and services 
through direct-to-consumer (DTC) adver-
tising, enabling patients to bypass physi-
the type of information that is provided 
to "consumers" through the commercial 
market. 4 Companies who manufacture 
products necessarily participate in the 
creation of consumer demand, precluding 
the provision of consumer information 
that is unbiased and sufficient. Irrespec-
tive of the fact that DTC marketing effec-
tively sidesteps physician involvement, 
there is also some question as to whether 
physicians themselves possess a level of 
knowledge adequate to comprehend these 
genetic tests and explain their import to 
Ms. Roxanne Mykitiuk their patients. 
cian involvement. 1 In Canada, the perceived desire 
for access to genetic tests outside the public system 
is not only exploited but promoted through Internet 
availability. In the United States, DTC marketing of 
genetic testing through print and broadcast cam-
paigns has begun, which contributes to the perceived 
desire for such testing. For example, in the fall of 
2002, Myriad Genetics, Inc. (Myriad) began a DTC 
advertising campaign for its product BRACAnalysis 
(which tests for risk of breast and ovarian cancer) in 
both print and broadcast media. 
The surge in recent advances in human genetics 
has fostered a trend towards commercialization, just 
as commercial interests have contributed to the 
© 2004 Canadian Medical Association 
In the absence of any meaningful regu-
lation restricting DTC advertising of genetic testing 
services, Canada is likely to witness an increase in 
print and broadcast advertising of genetic testing 
similar to the marketing campaigns now being 
launched in the USA. This article therefore has 4 
intents: 
1. to highlight the major players and targeted consu-
mers in the realm of private access to genetic test-
ing and DTC advertising 
2. to canvass arguments for and against private ac-
cess to commercially available genetic testing 
3. to analyze the recent DTC campaign by Myriad 
as an example of what may be on the horizon for 
Canada 
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4. to question the adequacy of Canada's current reg-
ulatory system to deal with advertisements of this 
nature and, by examining the routes taken in other 
jurisdictions, to explore the potential for an im-
proved regulatory framework specific to genetic 
testing services 
Access to commercial testing services for 
genetic susceptibility 
Currently, Canadians access genetic testing primarily 
through the public health care system. Patients typic-
ally visit their family physician; given a clinical pre-
sentation or family history suggestive of an inherited 
condition, they are then referred to a genetics depart-
ment in a hospital or cancer agency for genetic coun-
selling.1 In Ontario, 9 linked regional genetics centres 
in Hamilton, Kingston, London, Mississauga, North 
York, Sudbury, Oshawa, Ottawa and Toronto operate 
as a genetics network for the province.5 In November 
2001, base funding for the Provincial Regional Gen-
etics Program in Ontario was $39 million.5 In light 
of the rapid growth in genetic testing capabilities, sig-
nificant deliberation has been given to instituting a 
framework for the evaluation of public coverage of 
predictive genetic tests and services. To this end, the 
Ontario Provincial Advisory Committee on New Pre-
dictive Genetic Technologies ' recommended the 
assessment of 6 key factors in determining whether a 
particular genetic test will be granted provincial cov-
erage: technical accuracy; clinical effectiveness; use-
fulness to tested individuals; adverse and additional 
effects; expansion potential; and cost. 
Even if this comprehensive evaluation scheme is 
implemented, not all useful genetic tests will be cov-
ered by provincial health insurance plans. Moreover, 
access to government-funded tests will be limited to 
those individuals considered by their physicians and 
the referral centre to benefit clinically from testing.6 
Not all individuals who seek genetic testing will be 
able to access it. And whereas some people may feel 
relieved to be told that that they do not need genetic 
testing, others may feel neglected, fearful or anxious, 
and will turn to private options. 1 Similarly, the "mo-
tivated consumer" with access to the Internet will 
soon discover the quick and accessible testing ser-
vices that can be purchased privately.7-8 
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At present, only a handful of private Canadian lab-
oratories offer genetic susceptibility testing for adult-
onset condilions. Most Canadian companies focus 
their genetic interest instead on paternity testing 
(e.g., Helix Biotech) and pre- and post-natal diag-
nostics (e.g., Procrea). Although there are still few 
commercial genetic testing laboratories in the United 
Kingdom, the growing availability of genetic testing 
has prompted Britain's Human Genetics Commis-
sion to devise a thorough study of oversight (i.e., the 
regulation) of direct genetic testing.9 Public demand 
for direct genetic testing services was found to be 
fairly low: over 60% of those surveyed stated that 
they were "unlikely" or "very unlikely" to use home 
genetic testing. On the other hand, 81 % responded 
that they would consider genetic testing if offered by 
their physician. 
In contrast, many more American companies have 
been involved in genetic testing; in 1996, there were 
"approximately 200 laboratories providing 175 OOO 
genetic tests for over 300 diseases or conditions in 
the USA." 9 Although the majority of these tests are 
marketed to medical professionals, DTC advertising 
and supply is on the increase. Hundreds of commer-
cial Web sites now direct consumers to companies 
that provide paternity testing, DNA "fingerprinting" 
or pre-natal testing, most based in the USA.1 There 
are also companies in Canada and Europe that pro-
vide access to testing over the Internet. Of these Web 
sites, a dozen or so also direct consumers to adult 
genetic susceptibility testing companies, and 4 offer 
DTC genetic testing services themselves.2 Increas-
ingly, because of the "global marketplace" created 
by the Internet, provincial and national borders are 
becoming irrelevant. 
DTC genetic testing is possible because of the rel-
ative ease with which genetic material can be re-
trieved for laboratory analyses.1 In most cases, tests 
are done on samples collected through non-invasive 
means such as mouth swabs or saliva samples. Most 
laboratories make the process even easier for cus-
tomers by providing containers and detailed instruc-
tions for obtaining, packaging and shipping the sam-
ples, as well as referrals to local affiliated clinics if a 
blood sample is required. Payment for testing, either 
DTC or privately purchased but mediated by a 
physician, may be billed to a credit card through a 
j 
secure Web site or paid by a third party such as a pri-
vate insurer. 1 
Arguments in favour of direct-to-consumer 
supply of genetic testing 
A prime attraction for consumers of private genetic 
testing services, and one that marketing campaigns 
target specifically, is the potential for enhanced pri-
vacy and individual control of genetic information. 10 
Patients can order tests online without having to meet 
the criteria required to obtain them through a physi-
cian's office. 1 Also, as test results can be received at 
home, they are not automatically entered into medical 
records and therefore can be kept hidden from insur-
ers or employers. 1 This may be a significant incentive 
for consumers, especially in the United States where 
the link between employment status and health in-
surance makes genetic discrimination a concern. 11 
However, it should be noted that some jurisdictions 
have implemented and many others have recommen-
ded the implementation of regulations or legislation 
to avoid discrimination in the context of insurance. 12 
The privacy argument may have less weight in 
Canada and other countries where health coverage is 
provided universally regardless of one's health or 
employment status, although concerns about life in-
surance may remain. 1 Where a test is not covered un-
der a public health care system, genetic info1mation 
may be desired nonetheless and considered worth 
paying for, out of pocket. 13 Although a specific gen-
etic test may not be covered because of a lack of evi-
dence for clinical effectiveness, 1 consumers may 
have other motives to seek testing, including to re-
duce anxiety; to facilitate life planning; to initiate 
family discussions of issues such as social and psy-
chological support and responsibility to and for other 
family members; and to help people plan career 
changes. 13- 15 
A prominent argument in favour of DTC supply of 
genetic tests is consumer autonomy. Proponents of 
this view argue that the ability to obtain information 
about oneself, including information about one's 
potential risk of disease, is an individual right that 
should be restricted only in cases where the interests 
of others might be harmed.9 This view is consistent 
with the shift from paternalism to individual self-
Direct-to-consumer advertising and genetic tests 
dete1mination that characterizes current approaches 
to health care and underpins many of the arguments 
in favour of DTC advertising and supply of genetic 
testing services. 16 
Other potential benefits include better-informed 
consumers, which may lead to superior quality of 
care stemming from improved diagnosis; to better 
matching of therapy needs to the preferences of pa-
tients; and possibly to enhanced compliance with 
treatments. 11 Similarly, ads for genetic tests targeted 
directly to the public may have educational value if 
the information they provide is scientifically accu-
rate. Such advertisements may provide relevant in-
formation about testing that could lead to therapeutic 
interventions or increased disease surveillance. They 
may also raise awareness of community resources 
such as associations and support groups for those 
dealing with various genetic diseases and predisposi-
tions, and of options for parents and potential par-
ents about reproductive alternatives and screening 
tests for newborns. 18 Nevertheless, profit-driven edu-
cation is inherently suspect, and the public can be in-
formed and educated by more trustworthy means. 
Concerns about the direct supply of genetic 
testing services 
Genetic testing provides information that is often 
complex and difficult to understand; nevertheless, it 
may profoundly affect a person's sense of self and 
have important implications for family members. Pa-
tients who, in the estimation of their physicians, do 
not need or are unlikely to benefit from genetic test-
ing may nonetheless be influenced by marketing that 
plays on or increases anxiety, and may be harmed by 
the resulting genetic information. 19·20 Misunderstand-
ings about risk estimations, how the information 
should be integrated into a one's life, and what to ex-
plain to family members are frequent. 2122 
Consumers may gain a false sense of security from 
negative test results, spend limited financial resources 
on testing that could better be used elsewhere, or be-
come unnecessarily anxious about risk for disease.23 
Furthermore, individuals who have misunderstood 
information from genetic tests, received incorrect in-
formation or misinterpreted predictive health infor-
mation could consequently make poor health-related 
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decisions, such as delaying seeking medical advice, 
seeking inappropriate medical treatment, or making 
expensive and unproven lifestyle or dietary changes.9 
The risk of both physical and psychological harm 
thus justifies consumer protection relating to both the 
advertising and supply of health related products. 
As much as consumers may desire straightforward 
choices and "solid" information, genetics is a com-
plex and rapidly changing area. Cancer itself has a 
great many contributing factors beyond inherited 
genes, and the interactions are complicated and often 
unclear. The risks and uncertainties associated with 
genetic information are difficult for many physicians 
to grasp, 18 let alone the general public. DTC advertis-
ing of tests enables genetics companies to take 
advantage of peoples ' incomplete understanding of 
genetics and exploit their worries about their and 
their family's health and future. Advertising in gen-
eral plays on the emotions of the target audience and 
can not provide the type of information that consu-
mers need to make informed decisions, particularly 
about pharmaceutical and genetic products.24 
False positives and false negatives constitute ano-
ther concern. Currently there is little or no profes-
sional consensus in the scientific community about 
the clinical value of many genetic tests . For example, 
the BRACAnalysis test for breast and ovarian cancer 
was put on the market despite disagreement on the 
test's "appropriateness" at the time. 18 It is a conse-
quence of commercialization that commercial pres-
sures become the leading reason for the entrance of 
items into the marketplace, which may lead to the 
introduction of health care products prematurely.4 
In addition, inadequate opportunities for qualified 
genetic counselling may leave patients psychologi-
cally unprepared to deal with the genetic information 
they do receive. Genetic counselling for patients and 
families undergoing genetic susceptibility or diag-
nostic testing has become the standard of public 
health care in Canada, but only a few private com-
panies provide or require counselling as part of their 
genetic testing services. 
Given the current shortage of genetic counsellors, 
it will most likely be family physicians who will re-
ceive requests for access to private testing. They may 
have to interpret advertisements for interested pa-
tients, explain why tests may be inappropriate 17 and 
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provide additional counselling. This increase in 
workload will add to their stress, with serious con-
sequences for their patients. Time constraints may 
limit the effectiveness of their counselling, and many 
family physicians will not have had the necessary 
background in genetics, let alone specific training 
in counselling, to provide and interpret test results 
and help patients understand the complex scientific, 
social and psychological issues.25 Nor is it likely that 
physicians will have had the training to evaluate the 
validity of claims made by industry about the accur-
acy and benefits of testing.26 Thus, many family phy-
sicians may be open to the influence of companies' 
marketing strategies and unable to effectively criti-
cize the information they receive, as has been argued 
with respect to prescription drugs. 27 28 
DTC advertising and supply of genetic tests also 
raises concerns about strains on the financial resour-
ces of the health care system and has implications 
for equal access to health care services. Inappropri-
ate demands by patients for genetic testing can bur-
den public health funds; so can post-test costs such 
as counselling, follow-up of results and associated 
treatments-all of which are likely to be covered 
under the public health care system.29 
Access to and cost of genetic tests through public 
health care systems are controlled by the patent own-
ers, who legally control access to and development 
of any type of test, treatment or cure that uses the 
patent. For example, Myriad Genetics, Inc., owner of 
the Canadian patents for the BRCA 1 and BRCA2 
genes linked to hereditary breast cancer, is attempting 
to enforce its gene patents and oblige public agencies 
to provide BRCA testing exclusively through use of 
its BRACAnalysis test. 1 
Myriad 's monopoly over the BRCAl and BRCA2 
genes illustrates the growing phenomenon of bio-
technology companies patenting the development, 
marketing and provision of genetic tests and thera-
peutics. Public health care systems like Canada's 
could lose the ability to provide coverage for many 
types of genetic testing, since companies are driven 
to market their gene-based diagnostic products and 
therapeutics in a restrictive and costly fashion to re-
coup their research investments. 1 
There are also serious concerns about the safety, 
accuracy and quality control of commercial genetic 
tests. Regulatory agencies and oversight mechanisms 
are in place in the USA, Canada and other countries 
to inspect national laboratories and to review staff 
and technical qualifications. But even when present, 
these review mechanisms may be implemented by 
agencies that are understaffed and under-resourced, 
and able to respond only afte1ward to serious breaches 
in standards.8 Because the Internet allows companies 
to cross national borders, using the Internet as a mar-
keting and delivery mechanism enables testing pro-
viders to avoid being subject to the national regula-
tory regimes of a consumer's home country. Since 
there are as yet no international regulations for gen-
etic testing facilities, consumers will be unlikely to 
know if a given provider is meeting their local stan-
dards for safety and accuracy. 1 
Ontario's health care system facilitates quality as-
surance in genetic testing by integrating pre-test 
preparation, laboratory analysis and interpretation 
into clinical practice, along with support consulta-
tion about test results.5 The standards used by profes-
sionals and institutions when delivering other servi-
ces will apply to the provision of genetic testing and 
ancillary services integrated into Ontario's public 
health care system. Since the procedures of private 
laboratories are not transparent, there is no guarantee 
that they are implementing standards of quality as-
surance or confidentiality. 
In response to some of these concerns a number of 
Internet health service providers (not specifically 
genetic testing companies) have attempted some 
form of self-regulation. For example, some providers 
have chosen to adopt codes of ethics, such as the 
e-Health Ethics Initiative, Draft Code or the HON 
Code of Conduct for Medical and Health Web Sites 
(www.ihealthcoalition.org/ethics/ehcode.html and 
www.hon.ch/HONcode/Conduct.html, respective-
ly), that include guidelines about protection of priva-
cy, quality, authority and accuracy of information, 
and transparency of interests. 1 
Such efforts at self-regulation may convince legis-
lators that overt regulation is unnecessary; however 
more formal regulation and oversight is advised, par-
ticularly in the area of genetic testing services, to pro-
tect consumer privacy of personal health information 
and to ensure the accuracy of marketing claims and 
efficacy of tests. Given the international scope of 
Direct-to-consumer advertising and genetic tests 
commercial health care provision, national govern-
ments must also work toward harmonizing regula-
tion and oversight mechanisms. 1 
An example of DTC marketing of genetic 
susceptibility testing: the Myriad campaign 
Myriad's DTC advertising campaign for breast can-
cer testing, which included both broadcast and print 
media, was piloted beginning September 13, 2002 in 
Denver and Atlanta. According to Myriad's press 
release, the "campaign is designed to alert women 
with a family history of cancer to recent advances in 
cancer prevention and early disease detection. lt is no 
longer appropriate for these women to simply consi-
der breast cancer their destiny, even in the context of 
a strong family history of the disease." Myriad goes 
on to say that "medical interventions have been 
shown to be effective in lowering the risks of cancer 
in individuals [with a family history of the disease] ." 
Whereas their earlier marketing and educational ef-
forts had been aimed toward cancer specialists, they 
state that there is now a need to "reach those with a 
family history of breast or ovarian cancer who do not 
themselves have cancer," because this group of indi-
viduals "stands to benefit the most" from this tool of 
predictive medicine. 
The broadcast ad features several women each stat-
ing their concern about breast cancer and the benefits 
of taking a BRACAnalysis test. They appear calm 
and in control, as if the knowledge they have gained 
from taking the test has made them more confident. 
Toward the end of the minute-long advertisement, a 
woman's voice explains that BRACAnalysis "can 
help you see the big picture." 
The ad is notable in several ways. First, it features 
women of visibly diverse racial origins, almost all 
apparently between the ages of 30 and 45. The cam-
paign is aimed at women between the ages of 25 and 
54 and targets major cities with large minority popu-
lations: Hispanics in Denver and African-Americans 
in Atlanta (Sandra Blum, BRACAnalysis Project 
Manager, Myriad Genetics, Inc., Salt Lake City, 
Utah: personal communication, 2002 Oct. 21). To 
achieve the broadest potential market Myriad is 
clearly attempting to demonstrate that the risk of 
breast cancer cuts across the population. Moreover, 
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by targeting relatively young women in their thirties 
and early forties, the campaign is attempting to cap-
ture women with significant disposable income, at 
an age when they are making important choices 
about career and family life. The BRACAnalysis 
Integrated Awareness Campaign ran for 5 months 
and included ads broadcast during major television 
shows, including ER, The Practice, CSI: Miami, 
Providence, Oprah, Regis and Kelli, and The Today 
Show. In addition, print advertisements ran in re-
gional versions of publications such as Better Homes 
and Gardens, The Ladies' Home Journal and 
Women's Health Monitor. The choice of many of the 
marketing venues indicates an attempt by Myriad to 
target a demographic of women who already have a 
general interest in issues relating to health and well-
being. 
Second, the fact that the ad never uses the words 
"gene" or "genetic" but instead talks about "family 
history" implies to viewers that BRACAnalysis can 
identify individuals at risk for heritable forms of 
breast cancer. This is a sweeping and exaggerated 
claim: BRACAnalysis can only identify 2 genetic 
mutations associated with about 7% of all breast 
cancers.1n 
Third, the ad suggests that a woman who takes the 
test will be able to "reduce her risk through effective 
medical options," but these options are never identi-
fied. Instead, the ad cultivates an overall impression 
that taking "a simple blood test" will enable the 
viewer to reduce her risk of breast cancer. The un-
certainties of genetic testing are downplayed, and the 
lack of professional consensus on the clinical valid-
ity and efficacy of the test goes unmentioned. The 
symbolism of the "big picture" theme that pervades 
the ad covertly implies that the advertisement is pro-
viding thorough and unbiased information. 
Fourth, the ad cleverly plays on 2 common themes 
often used in pharmaceutical advertising.31 On the 
one hand, the ad promotes the idea of interventionist 
medicine, which places a high value on action while 
rejecting the "wait and see" model of health care.31 
Traditionally, the "Lake-action" approach to health 
care refers to the notion of physician control. This 
emphasis on medical intervention creates a chain be-
tween manufacturer, advertisement and doctor, with 
the ultimate profit going to drug companies or, in 
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this case, genetics testing companies.' ' 
On the other hand, by advertising BRACAnalysis 
directly to the consumer, Myriad introduces the sec-
ondary concept of "participatory and autonomous 
roles in the context of medical decision-making."31 In 
drawing on the theme of "choice," Myriad's ads 
"validate patients ' worries about their genetic risks 
and appeal to their desire to assert control over po-
tential outcomes." 18 This encourages the move away 
from the paternalistic doctor-patient relationship and 
stresses the consumer's right to gain knowledge 
about their own risk for disease and hence their right 
to be in control. 
Interestingly, the voice-over at the end of the broad-
cast ad states "Talk to your doctor," which seems to 
dismiss the notion of consumer autonomy. Con-
versely, this statement gives viewers the impression 
that physicians will corroborate the "information" 
from the ad, and grants patients who have decided to 
undergo BRACAnalysis testing the reassurance that 
they are making the proper choice. Thus, the adver-
tisement conveys the notion that the medical profes-
sion does not have a monopoly on knowledge about 
our bodies, and reinforces the notion that patients will 
reap a benefit from choosing to act autonomously 
and get a genetic test. 
Fifth, contrary to Myriad's claim that BRACAnalysis 
is the tool of choice for women to reduce their risk 
of breast cancer, the ad's repeated use of the words 
"risk" "choose" and "ready" demonstrates that the 
campaign's true purpose is to heighten the percep-
tion of risk of cancer among a broader segment of 
women than would be identified through physician 
advice or evidence-based medicine. Playing on 
women's fears and suggesting that all women are at 
risk is a common feature of DTC pharmaceutical ad-
vertising.32 
Overall , there is little doubt that the main objective 
of the ad campaign is to target women and to bypass 
the role of physicians as the gate-keepers of medical 
knowledge, despite claims to the contrary that it is 
an "integrated" campaign addressed both to physi-
cians and to women with a family history of the dis-
ease. Interestingly enough, the product manager for 
BRACAnalysis indicated that the campaign was 
aimed at women because they are known to be the 
managers of health care in the family and not just 
because the incidence of breast cancer is much 
higher in women. Just days into the campaign, 
Myriad cited with pride the 40 phone calls a clay 
received on their toll-free number as a direct result 
of the campaign. 11 
Myriad asserts that since physicians are not ade-
quately informed about genetics and testing, a DTC 
advertising campaign is warranted to educate con-
sumers so they can make better health-care deci-
sions. There is some credibility to this argument in 
private systems like that of the United States, where 
no governing public body bears the responsibility for 
promoting consumer awareness and undertaking 
health education programs. In Canada's public 
health systems, this responsibility lies with provin-
cial health departments; in Britain's, with the Na-
tional Health Service. The danger is that the infor-
mation provided is motivated by market incentives 
and is thus is not primarily designed to educate. 
Current regulations of DTC supply and 
advertising of genetic testing in Canada 
The advertising of pharmaceutical drugs and med-
ical devices in Canada is governed by the Food and 
Drugs Act33 and the Broadcasting Act,34 but there is 
nothing in these Acts or their regulations that would 
prohibit or regulate DTC advertisements of genetic 
testing similar to Myriad's campaign in the USA. 
The Food and Drugs Act prohibits advertising to 
the public of any food, drug, cosmetic or device as a 
treatment, prevention or cure for a number of dis-
eases indicated in a schedule in the legislation.33 A 
"device" is any article, instrument, apparatus or con-
trivance that is manufactured, sold or represented for 
use in the diagnosis, treatment, mitigation or preven-
tion of a disease. 33 
It is uncertain whether a device, as defined, includes 
commercial genetic test kits, since the uses listed 
may not fully describe the purpose of a genetic test 
such as the BRACAnalysis product. The Medical 
Devices Bureau, an agency enabled by the Medical 
Devices Regulations and the Food and Drugs Act, is 
responsible for issuing licences to manufacturers to 
sell medical devices in Canada. Sections 26 and 27 
of the Medical Devices Regulations control the ad-
vertising of products that fall under Class UI, mean-
Direct-to-consumer advertising and genetic tests 
ing they present a moderate risk in terms of public 
health implications.35 These provisions indicate that a 
licence must be held in order to sell genetic tests, and 
that if they are advertised there must be a warning 
stating that they may not have been licensed in accor-
dance with Canadian law. Before the product is avail-
able for sale in Canada, a pre-market review is done, 
at which time a genetics company will attempt to ob-
tain a licence by satisfying safety effectiveness and 
clinical standards. Advertising is a post-market activ-
ity under the mandate of the Inspectorate. Identifying 
which oversight bodies are expected to regulate DTC 
advertising tells only half the story: tight government 
resources and pressure in Canada to lift restrictions 
on DTC advertising means that the agencies with the 
mandate to regulate in this area are having difficulty 
doing so. 36 
It is important to note that what is actually being 
regulated by the aforementioned legislation and regu-
lations are commercially offered genetic test kits that 
might be marketed to individuals for their own pri-
vate use, rather than genetic testing that is offered as 
a service. For the most part what is on offer today, 
and what consumers are purchasing, are not genetic 
test kits but testing services that fall outside the scope 
of current legislation. 
Furthermore, the content of ads of this nature are 
not subject to regulation under the Broadcast Act, but 
to a voluntary system of regulation through voluntary 
adherence to guidelines established by the Pharma-
ceutical Advertising Advisory Board (PAAB). An or-
ganization of interested groups, including manufac-
turers, PAAB has developed a Code of Advertising 
Acceptance for what they term advertising and pro-
motion systems. The advisory board operates inde-
pendently of government regulatory structure. The 
PAAB Code37 applies to "all communications in 
which claims, quotations and references are made for 
single-entity and compound prescription and non-
prescription (over-the-counter) pharmaceutical prod-
ucts." Moreover, a pharmaceutical product is defined 
as "a substance or mixture of substances manufac-
tured, sold or represented by a specific manufacturer 
for in vivo use in the diagnosis, treatment, mitigation 
or prevention of a disease, disorder, abnormal physi-
cal state, or in restoring, correcting or modifying 
function(s) in humans." Again, it is necessary to ex-
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amine the purpose of the product put forth by the 
manufacturer to determine whether or not it fits into 
the PAAB Code's definition and is thus subject to 
regulation. It is questionable whether genetic tests 
will ever fit this definition. 
An examination of how DTC advertising and sup-
ply of genetic testing is regulated in other countries 
identifies paths Canada could follow in developing 
its own regulatory scheme. 
Future regulatory framework: ideas from 
other jurisdictions 
The British Human Genetics Commission found that 
in the United Kingdom there was a general interest 
in placing restrictions on advertising of DTC genetic 
testing. Many of the Commission's general recom-
mendations on DTC advertising and supply of gen-
etic testing are pertinent to the develoment of a regu-
latory scheme for Canada. 
Current controls on genetic testing in the United 
Kingdom include the Advertising Standards Author-
ity, which administers the British Codes of Advertis-
ing and Sales Promotion. Many of those participate-
i n g in the Commission's study supported 
strengthening the Codes, especially in relation to di-
rect genetic testing services, which could take the 
form of an additional section in the Codes with spe-
cific requirements.9 The report stated that most ge-
netic tests that provide predictive health information 
should not be supplied directly to the public or 
through a non-medical health professional such as a 
pharmacist. For direct genetic tests to be provided 
over-the-counter, a manufacturer would have to 
"convince a regulator that the test is sufficiently well 
validated and that anyone involved in providing the 
test has the right training and expertise to give good 
quality advice to the consumer," 9 an approach that 
resembles the way medicinal products classified as 
"pharmacy-only" are regulated. 
In the United States, both the Food and Drug Ad-
ministration and the Federal Trade Commission have 
roles to play in monitoring advertisements of genetic 
tests, yet neither has exercised their authority in this 
area. 18 Some suggest that "shared oversight" of DTC 
advertising of genetic testing by these administrations 
would help ensure that advertisements provide infor-
30 Med clin exp• vol 27, n° l,fevrier 2004 
mation about the risks as well as the benefits of using 
genetics tests and avoid hyperbolic statements about 
their effectiveness. 18 After the Myriad campaign, the 
Centers for Disease Control and Prevention also 
launched a study similar to that of the British Com-
mission to investigate the effects of DTC advertising 
of genetic testing. 
Regardless of the regulatory mechanisms put in 
place for the advertising and supply of genetic test-
ing, Canadians will remain exposed to advertising 
through American and internationally based Web 
sites- thus the additional need for Internet regula-
tion. The CRTC has already stated that it will have no 
role to play in the development of regulations for the 
Internet. 1 
While ideas from other jurisdictions may prove to 
be instructive, to understand the full implications of 
DTC advertising of genetic testing the particulars of 
Canada's health care system must be considered. 
Canada's "ad hoe nature of decision-making and 
diversity [of] service coverage within provincial 
health-insurance plans" may mean that OTC adver-
tising will be especially effective, since beneficial 
genetic services might not be covered consistently 
across Canada (Bryn Williams-Jones, '"Be ready 
against cancer, now': Myriad Genetics' direct-to-
consumer advertising campaign," currently under 
peer review; on file with RM.). Moreover, given the 
existence of the global marketplace, the choice of 
regulatory framework will be conditioned not only 
by federalism but also by Canada's obligations under 
and participation in various international trade agree-
ments. 
Conclusion 
Private genetics companies seek new and expanded 
markets in which to sell their products. Increasingly, 
jurisdictions have become targets of DTC advertising 
campaigns marketing genetic tests. The concern is 
that this trend will soon penetrate the Canadian mar-
ket as well. Without proper and thorough regulation, 
the only guiding principle with respect to decision-
making on genetic testing will be caveat emptor, a 
principle strikingly out of place in a health care sys-
tem structured around physician responsibility and 
protection of patient interests. 
The problems explored in this article with respect 
to OTC advertising and supply of genetic tests de-
mand further study. We need to investigate possible 
regulatory frameworks appropriate to a publicly 
funded health care system. If left only to the principle 
of caveat emptor, the danger is that a "buyer beware" 
mentality will come to characterize the relationship 
between physician and patient, subtly transforming 
the Canadian health care environment. 
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